Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :28920959
Publication Date : 2017/09/18

Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.


Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has substantially extended patient survival. However, TKIs primarily target differentiated cells and do not eliminate leukemic stem cells (LSCs). Therefore, targeting minimal residual disease to prevent acquired resistance and/or disease relapse requires identification of new LSC-selective target(s) that can be exploited therapeutically. Considering that malignant transformation involves cellular metabolic changes, which may in turn render the transformed cells susceptible to specific assaults in a selective manner, we searched for such vulnerabilities in CML LSCs. We performed metabolic analyses on both stem cell-enriched (CD34(+) and CD34(+)CD38(-)) and differentiated (CD34(-)) cells derived from individuals with CML, and we compared the signature of these cells with that of their normal counterparts. Through combination of stable isotope-assisted metabolomics with functional assays, we demonstrate that primitive CML cells rely on upregulated oxidative metabolism for their survival. We also show that combination treatment with imatinib and tigecycline, an antibiotic that inhibits mitochondrial protein translation, selectively eradicates CML LSCs both in vitro and in a xenotransplantation model of human CML. Our findings provide a strong rationale for investigation of the use of TKIs in combination with tigecycline to treat patients with CML with minimal residual disease.

Authors : Kuntz Elodie M , Baquero Pablo , Michie Alison M , Dunn Karen , Tardito Saverio , Holyoake Tessa L , Helgason G Vignir , Gottlieb Eyal ,

Related products :

Catalog number Product name Quantity
T18-023-T1 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-023-T2 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-021-N2 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-021-T1 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-021-T2 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-021-N1 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-023-N2 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-022-N1 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-022-N2 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-023-N1 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-022-T1 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-022-T2 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) 0.1 mg
T18-021-T1 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) tissue 0.1 mg
T18-023-T1 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) tissue 0.1 mg
T18-022-T1 Matched Tumor_ Normal Human Leukemia, bone marrow Tissue Lysates (Chronic Myeloid Leukemia) tissue 0.1 mg
BYA9643-1 CD13, Aminopeptidase N, Chronic Myeloid Leukemia, 150kD, Clone WM_47, Mab anti_Human vial
SIH-222-50MG FCCP Inhibits mitochondrial oxidative phosphorylation CAS Number 370_86_5 50mg
SIH-222-10MG FCCP Inhibits mitochondrial oxidative phosphorylation CAS Number 370_86_5 10mg
29-916 Mitochondrial uncoupling proteins (UCP) are members of the larger family of mitochondrial anion carrier proteins (MACP). UCPs separate oxidative phosphorylation from ATP synthesis with energy dissipat 0.1 mg
31-062 DOK1 is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210 (bcr 0.05 mg
31-076 DOK2 is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210 (bcr 0.05 mg
AD-102-B Acute myeloid leukemia cells (KH1C12), DNA Aptamer, Biotinylated Custom
AD-102-U Acute myeloid leukemia cells (KH1C12), DNA Aptamer, unlabeled Custom
AD-102-F Acute myeloid leukemia cells (KH1C12), DNA Aptamer, FITC labeled Custom
EIAAB24926 Hematopoietic lineage switch 7,Hls7,Mlf1,Mouse,Mus musculus,Myelodysplasia-myeloid leukemia factor 1,Myeloid leukemia factor 1


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur